Sarepta Therapeutics Inc Announces Top-line Results from Part 1 of Study SRP-9001-102 Conference Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the Sarepta Therapeutics' Micro-dystrophin SRP-9001-102 Top Line Clinical Data (Part One) Conference Call and Webcast. (Operator Instructions) As a reminder, today's program is being recorded.
At this time, I'll turn the call over to Doug Ingram, President and CEO, for opening remarks. Please go ahead.
Thank you very much. Before I begin, let's move to the next slide, please.
I would just remind everyone that we will be, of course, very likely making forward-looking statements today. And I would ask folks to look to our public filings and SEC filings for the various risks and uncertainties that are intended when one makes forward-looking statements about the potential issues that'll occur in the future.
And with that, let's go to the next slide. Good afternoon. Thank you for joining all of us today for our investor conference call to review the top line results from our Part 1 interim analysis of Study
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |